Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02309567 : Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?
PhaseN/A
AgesMin: N/A Max: N/A
Eligibility
Inclusion Criteria:

- patients who were referred to our department with the purpose of 18F-FDG PET/CT
imaging for staging due to lung cancer diagnosis

- patients who were performed 18F-FDG PET/CT for diagnosis in the cause of the
suspected pulmonary nodule/lesion in thorax CT but not detected pathologic FDG
accumulation

- In the control group, healthy subjects with no history of cancer and without any
complaint

Exclusion Criteria:

- Patients had operated for lung cancer, received prior chemotherapy or radiotherapy
for lung cancer, with no definitive histological diagnosis, and a blood glucose level
greater than 150 mg/dL
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02309567      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740